Comparison of Efficacy and Peripheral Neuropathy of Solvent-based Paclitaxel with Paclitaxel Poliglumex and NK105: A Systematic Review and Metaanalysis

Author(s): Azade Taheri*, Amirhossein Rad, Erfan Sadeghi, Jaleh Varshosaz

Journal Name: Current Pharmaceutical Design

Volume 27 , Issue 17 , 2021

Become EABM
Become Reviewer
Call for Editor


Background and Introduction: Peripheral neuropathy is one of the most common dose-limiting side effects of solvent-based paclitaxel. Paclitaxel poliglumex (PPX) and NK105 were developed to overcome the paclitaxel induced peripheral neuropathy. However, the incidence of peripheral neuropathy induced by PPX and NK105 was reported higher than solvent-based paclitaxel, but evidence remains inconsistent.

Methods: The article was reported in accordance with PRISMA Guidelines (Registration number: CRD42021245313). We conducted a meta-analysis to compare the incidence and severity of peripheral neuropathy between solvent-based paclitaxel, PPX and NK105 mono-chemotherapy.

Results: Results revealed that no significant difference exists between the incidence of all grade peripheral neuropathy among the solvent-based paclitaxel, PPX and NK105 treated groups. While, the incidence of high grade peripheral neuropathy induced by NK105 was lower than two other groups. Moreover, the overall survival was not improved in PPX compared with other groups. However, NK105 demonstrated significant longer overall survival in patients with cancer.

Conclusion: Current evidence suggests more attention should be paid to the paclitaxel poliglumex re-formulation.

Keywords: Incidence, peripheral neuropathy, paclitaxel poliglumex, NK105, solvent-based paclitaxel, meta-analysis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2021
Published on: 17 September, 2020
Page: [2041 - 2055]
Pages: 15
DOI: 10.2174/1381612826666200917145551
Price: $65

Article Metrics

PDF: 167